THU0354 DISEASE WORSENING AND SAFETY IN PATIENTS SWITCHING FROM ORIGINATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB (CT-P13) IN THE RANDOMIZED NOR-SWITCH-STUDY: EXPLORATIVE ANALYSIS IN SPA PATIENTS

Methods:
Patients were randomized 1:1 to continued INX or switch to CT-P13. Serum drug levels were analyzed by automated in-house assay. The primary endpoint was disease worsening according to disease-specific composite measures and/or consensus between investigator/patient. Exploratory subgroup analyses examined disease worsening and safety in SpA. The primary endpoint was analysed by logistic regression, adjusted for diagnosis and disease duration. Results: Demographics, occurrence of disease worsening, change in disease measures and treatment-emergent adverse events (TEAE) were similar (Table) , as were serum drug levels for INX and CT-P13 ( Figure) .
Conclusions:
Explorative analyses in the NOR-SWITCH study showed similar efficacy, drug levels and safety in SpA patients switched to CT-P13 as those on continuous INX. The study was not powered to show non-inferiority within each diagnosis. 
Methods:
The 53 patients with AS (42 male, 9 female, average age is 37.6 years old, duration of disease is 14-152 month) were included into study. All patients were treated by NSAIDs and sulfasalazine (2 g per day) at least 3 month before study. In treatment of 27 patients (1st group) was added adalimumab (40 mg subcutaneously every 2 weeks), other 26 patients (2nd group) were left on previous treatment regime. Patients were observed during 12 months of treatment including measurements of pain visual analog scale (VAS) in hip movements, maximal distance between ankles, pelvic X-ray and sonography of hip joints by 10-18 MHz probe. BASRI-Hips index was applied for radiographic estimation of structural damage of hip joints [3] . During sonography width of hip joint capsule and hyaline cartilage were measured. The Mann-Whitney-U test was used for comparison of changes in clinical and sonographic data between two groups of patients. Background: Five different sub-cutaneous TNF alpha blockers (TNFb) are available for the treatment of NSAID-refractory and active axial spondyloarthritis (axSpA). The efficacy of these drugs in axSpA has been well reported in several RCT and real-life studies separately or as a group, but only very few head-to-head studies have compared each molecule's treatment effect in axSpA. Also, some data suggest that TNFb treatment effect in patients failing to a first TNFb is poorer than in TNFb-naïve patients, but some other suggest that response to a second TNFb might be comparable. Objectives: to describe TNFb prescription and treatment response of each TNFb, and to compare treatment response in TNFb-naïve/not naïve axSpA patients in a real-life setting. Methods: Prospective, multicenter, usual care study with 2 visits (baseline and 12 weeks after TNFb initiation, Predict-SpA study, ClinicalTrials.gov: NCT03039088)). Patients: axSpA patients (diagnosis according to treating rheumatologist) initiating a TNFb. Data collection: Patients and disease characteristics at baseline. Previous exposure to TNFb was collected. Disease activity and function measures were collected at both visits. The choice of the TNFb to be started during the trial was at the treating rheumatologist's discretion. Statistical analysis: effectiveness was defined by the BASDAI50 response. Non-responder imputation and baseline observation carried forward imputation (for binary and continuous outcome variables, respectively) were performed for patients who discontinued the TNFb treatment between baseline and the follow-up visit. Results: Among the 527 patients enrolled in the study, 508 patients were included in the analysis (1 patients was excluded due to missing data on all disease activity measures at baseline, and 18 patients were excluded due loss of follow-up between baseline and the follow-up visit). Mean age was 41.4 (±11.6), 237 (47%) were women, with a 6.1±8.5 mean disease duration. 377/508 (74%) were TNFb-naïve while 66 (13%), 35 (7%),19 (3.7%),8 (2%) and 3 (1%) had previously received, 1,2, 3, 4 and >4 TNFb, respectively. In the whole study population the most frequently prescribed TNFb was etanercept (197 (39%)), followed by adalimumab (131 (26%)), golimumab (88 (17%)), infliximab 53 (10%) and certolizumab (39 (8%)); the same order was observed in TNFb naïve patients; however, in patients previously exposed to TNFb, the most frequently prescribed TNFb was infliximab (31 (24%)) followed by golimumab (29 (22%)), adalimumab (29 (22%)), certolizumab (22 (17%)) and etanercept (20 (15%)). BASDAI50 responses were comparable for all TNFb molecules: 52%, 52%, 48%, 53% and 49% for etanercept, adalimumab, golimumab, infliximab and certolizumab, respectively. BASDAI 50 response was comparable in patients TNFb-naïve and patients previously exposed to only 1 previous TNFb (53% vs. 52%, for naïve vs. nonnaïve patients) but significantly decreased after (i.e. 37% and 36.% for patients previously exposed to 2 and to 3 or more TNFb) Conclusions: this study suggests that the TNFb treatment response is similar across the different available molecules but this treatment response decreased in case of a previous use of two TNFb.
